Profile of salivary gland flow dysfunctions in patients with differentiated thyroid carcinoma submitted to radioiodine therapy

AUTOR(ES)

Vieira, Anna Clara Fontes, Rodrigues, Aline Sampaio Lima, Cruz, Maria Carmen Fontoura Nogueira da, Lopes, Fernanda Ferreira

FONTE

Braz. J. Oral Sci.

DATA DE PUBLICAÇÃO

2013-09

RESUMO

AIM: To evaluate the effects of radioiodine therapy on salivary flow in patients with differentiated thyroid cancer. METHODS: A sample comprising 88 patients submitted to ablation with iodine 131 was included in the study. The patients were submitted to sialometry and evaluation of the presence of xerostomia before, 10 days and 3 months after radioiodine therapy. RESULTS: Xerostomia was observed in 36.4% of the patients before radioiodine therapy, 59.15% at 10 days after therapy, and 25% at 3 months after therapy. Significant differences were observed in non-stimulated salivary flow rates between the second and third evaluations (p<0.020) and in stimulated salivary flow between the first and second evaluations (p<0.010). CONCLUSIONS: The results suggest that changes in salivary flow resulting from radioiodine therapy are more pronounced during the first weeks after treatment and seem to regress after 3 months.

Documentos Relacionados

• Radioiodine-induced oxidative stress in patients with differentiated thyroid carcinoma and effect of supplementation with vitamins C and E and selenium (antioxidants)
• Improving care of patients with low-risk differentiated thyroid carcinoma
• Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
• Epidemiological profile of 175 patients with Crohn's disease submitted to biological therapy
• Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma